SequelSEC

Aurinia Pharmaceuticals Inc. AUPH

Pharmaceutical Preparations · CIK 0001600620 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$83.70M
Fiscal year ended 2026-09-30
Operating income
$35.36M
Fiscal year ended 2026-09-30
Free cash flow
Unavailable
Fiscal year ended 2026-09-30

Valuation, from the filing

Public float$1.00BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$7.52Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income3.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue3.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Net margin101.5%97th
Operating margin37.1%97th
Effective tax rate-151.6%6th
R&D / revenue11.5%16th
Gross margin88.5%81th
SBC / revenue5.2%21th
Revenue YoY growth20.4%66th
Current ratio5.25x62th

Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $83.70M and net income of $31.70M for the fiscal year ended 2026-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Aurinia Pharmaceuticals Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Aurinia Pharmaceuticals Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Revenue$83.70M$83.22M$77.70M$77.11M$73.47M$70.01M$62.46M$59.87M$67.77M$57.19M
Cost of revenue$8.31M$6.56M$6.50M$8.80M$8.18M$7.12M$8.57M$5.55M$6.04M$8.91M
Gross profit$75.39M$76.66M$71.20M$68.32M$65.29M$62.89M$53.89M$54.32MUnavailableUnavailable
Operating income$35.36M$46.34M$41.42M$33.24M$29.74M$20.08M$21.85M-$1.67M$11.75M-$1.51M
Net income$31.70M$37.41M$34.36M$210.79M$31.55M$21.51M$23.34M$1.43M$14.35M$722.00K
Research & development$16.61M$13.05M$7.47M$10.90M$8.44M$7.43M$5.74M$8.11M$3.05M$4.08M
Weighted-average diluted sharesshares 135.17Mshares 133.53Mshares 137.64MUnavailableshares 136.01Mshares 137.53Mshares 143.20MUnavailableshares 145.65Mshares 144.11M
Pretax income$38.72M$48.79M$43.92M$35.69M$31.96M$22.16M$24.35M$1.17M$14.81M$1.48M
Income tax expense$7.01M$11.37M$9.57M-$175.10M$411.00K$643.00K$1.00M-$256.00K$457.00K$756.00K
Diluted EPS$0.23$0.28$0.25$1.53$0.23$0.16$0.16$0.01$0.10$0.01
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$24.68M$23.51M$22.03M$29.26M$26.18M$26.02M$20.34M$37.03M$42.37M$44.93M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Aurinia Pharmaceuticals Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Cash & equivalents$45.79M$179.73M$40.75M$80.16M$72.89M$52.91M$66.11M$83.40M$36.63M$33.26M
Total assets$825.70M$792.26M$724.00M$751.59M$527.53M$502.56M$504.85M$550.64M$549.36M$523.53M
Current assets$587.89M$541.32M$480.24M$491.97M$438.74M$408.97M$405.76M$446.60M$440.46M$409.67M
Total liabilities$168.18M$177.40M$156.37M$170.26M$161.76M$167.26M$154.66M$173.17M$161.36M$158.91M
Current liabilities$96.00M$99.89M$86.56M$93.72M$76.22M$78.27M$68.41M$97.76M$78.61M$76.90M
Total equity incl. NCI$657.52M$614.86M$567.63M$581.33M$365.77M$335.30M$350.19M$377.48M$388.00M$364.62M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$43.73M$45.15M$46.41M$45.69M$44.79M$46.50M$46.20M$39.23M$38.71M$38.85M
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.01M$1.74M$2.66M$3.31M$2.21M$3.31M$4.22M$5.19MUnavailableUnavailable

Cash flow

Aurinia Pharmaceuticals Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Operating cash flow$46.37M$52.57M$32.56M$45.67M$44.45M$44.24M$1.30M$30.11M$17.03M$15.84M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$175.73M$81.45M-$18.08M-$36.76M-$13.77M-$13.27M$31.03M$39.22M-$10.57M-$38.62M
Financing cash flow-$4.32M$4.81M-$53.68M-$1.89M-$10.49M-$44.39M-$49.34M-$23.05M-$2.72M-$8.27M
Net change in cash-$133.69M$138.82M-$39.20M$7.02M$20.19M-$13.43M-$17.00M$46.29M$3.74M-$31.05M
Stock-based compensation$6.12M$2.84M-$866.00K$6.73M$5.92M$5.44M-$3.41M$8.95M$8.33M$8.59M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$0$38.72M$36.16M$0$8.67M$42.56M$46.92M$21.80M$0$6.13M
Depreciation & amortization$4.84M$4.83M$4.82M$4.86M$4.86M$4.86M$4.86M$4.86M$4.89M$4.84M

Derived

Aurinia Pharmaceuticals Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin90.1%92.1%91.6%88.6%88.9%89.8%86.3%90.7%UnavailableUnavailable
Operating margin42.3%55.7%53.3%43.1%40.5%28.7%35.0%-2.8%17.3%-2.6%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue7.3%3.4%-1.1%8.7%8.1%7.8%-5.5%14.9%UnavailableUnavailable
Current ratio6.12x5.42x5.55x5.25x5.76x5.23x5.93x4.57x5.60x5.33x
Revenue YoY growth13.9%18.9%24.4%28.8%8.4%22.4%24.2%32.8%24.3%37.8%
Net margin37.9%UnavailableUnavailable273.4%42.9%UnavailableUnavailable2.4%21.2%1.3%
R&D / revenue19.8%15.7%9.6%14.1%11.5%10.6%9.2%13.5%UnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate18.1%23.3%21.8%-490.6%1.3%2.9%4.1%-21.8%3.1%51.2%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AUPH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-30View SEC filing
10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-07-31View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

7 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2024-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-03-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.